Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1), also known as T-cell immune regulator 1, is a multi-pass membrane protein that functions as the a3 subunit of the V0 domain within the vacuolar-type H+-ATPase (V-ATPase) complex [UniProt Q13488]. It is highly expressed in osteoclasts, where it is indispensable for the acidification of the resorption lacuna, allowing for the dissolution of bone mineral during remodeling [Nature Genetics 25.3 (2000): 343-346]. TCIRG1 also plays a significant role in the immune system, specifically in T-cell activation and the regulation of intracellular pH in various organelles [Gene 220.1-2 (1998): 41-49]. Mutations in the TCIRG1 gene are responsible for approximately 50% of cases of infantile malignant osteopetrosis, a severe genetic disorder characterized by abnormally dense bone and bone marrow failure [UniProt Q13488, Nature Genetics 25.3 (2000): 343-346]. In the context of oncology, TCIRG1 is frequently overexpressed in various cancers, where it facilitates extracellular acidification, promoting protease activity and tumor cell invasion [Journal of Biological Chemistry 284.23 (2009): 15490-15500]. Although it represents a potential therapeutic target for metabolic bone diseases and metastatic cancer, the high conservation of V-ATPase subunits across tissues presents significant challenges for achieving isoform-specific inhibition and avoiding systemic toxicity [PNAS 85.21 (1988): 7972-7976, British Journal of Pharmacology 151.3 (2007): 323-333].
Inhibition of the V0 domain of the V-type ATPase complex, thereby blocking proton translocation across the plasma membrane or organelle membranes.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1) (TCIRG1).